The debate pitting AI safety against AI opportunity presents a false choice. Historical parallels, like the railroad industry, show that safety regulations (e.g., standardized tracks, air brakes) were essential for enabling greater speed, reliability, and economic potential. Trustworthy AI will unlock greater opportunity.

Countering calls for government-mandated slowdowns, Zuckerberg's position is that AI labs already face sufficient incentives to ensure safety. He argues that model safety is a product feature that is economically rewarded, and that the reputational and financial consequences of releasing an unsafe model are enough to enforce responsible pacing by individual companies.

Vance argues that AI companies creating potentially dangerous models have a responsibility to build and release defensive countermeasures. He views their calls for government regulation as an attempt to shirk this responsibility, rather than a genuine safety effort.

Productive AI safety work isn't debating "Terminator" scenarios but building practical cybersecurity tools for immediate threats. This includes creating systems to prevent prompt injection, develop agent swarm "kill switches," and ensure provenance, treating safety as an engineering problem to be solved today.

The default assumption is that slowing innovation is inherently bad. With a technology as potent as AI, a deliberate slowdown is a feature, providing critical time to understand the systems, manage disruptions, and build governance structures before irreversible consequences occur. A true halt is not the alternative.

The view that safety measures hinder AI performance is a false dichotomy. A model's economic usefulness and profitability are directly tied to its controllability and predictability, making safety and alignment core product features rather than constraints.

AI expert Max Tegmark argues that regulation, like the FDA for pharma, would shift incentives. Instead of a 'race to the bottom' on unchecked capabilities, companies would compete to be first to develop provably safe AI. This would create a golden age of innovation in areas like medicine while sidelining riskier applications.

From an entrepreneurial perspective, delaying a product launch to invest in safety testing is strategically unsound. While it may be the moral high ground, it doesn't secure the next funding round. The market fundamentally rewards speed over caution, creating a systemic barrier to responsible AI development.

An FDA-style regulatory model would force AI companies to make a quantitative safety case for their models before deployment. This shifts the burden of proof from regulators to creators, creating powerful financial incentives for labs to invest heavily in safety research, much like pharmaceutical companies invest in clinical trials.